Voyager Therapeutics to Participate in Upcoming Investor Conferences
Voyager Therapeutics (Nasdaq: VYGR) announced its participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Voyager Therapeutics (Nasdaq: VYGR) announced its participation in two upcoming investor conferences. The first is Chardan’s 6th Annual Genetic Medicines Conference on October 4, 2022, featuring a company presentation at 3:45 p.m. ET. The second event is the Truist Securities Genetic Medicine Summit on October 20, 2022, where Voyager will participate in a CNS panel discussion (not webcast). Interested investors can access the presentation and archived webcasts on Voyager's website for 30 days following the events.
Details
News Market Reaction – VYGR
The recorded move for VYGR in the trading session of this news was +0.69%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced that management will participate in the following investor conferences:
- Chardan’s 6th Annual Genetic Medicines Conference, New York, NY – Company presentation, October 4, 2022, 3:45 p.m. ET
- Truist Securities Genetic Medicine Summit, New York, NY – CNS panel discussion (not webcast), October 20, 2022
The presentation may be accessed from the Investors section of Voyager’s website at www.voyagertherapeutics.com. Replays of webcasts are archived on the Company's website for at least 30 days.
About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the modality to treat devastating diseases. Proprietary capsids born from Voyager’s TRACER capsid discovery platform are powering a rich early-stage pipeline of programs and may elevate the field to overcome the narrow therapeutic window associated with conventional gene therapy vectors across neurologic disorders and other therapeutic areas.
voyagertherapeutics.com LinkedIn Twitter
Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.